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Inflammatory Bowel Diseases
Two independent studies by Rakoff-Nahoum et al.
(2006) and Uhlig et al. (2006) in this issue of Immunity
have illuminated a unique pathogenic role of innate
immunity via Toll-like receptor and interleukin-23 sig-
naling, respectively, in intestinal inflammation. These
data define new roads to gut inflammation and future
avenues for therapy.
It is well established that the adaptive immune system
plays a major role in driving the dysregulated immune
response against the commensal microflora in chronic in-
testinal inflammation (Sartor, 2006; Bouma and Strober,
2003). In contrast, the role of the innate immune sys-
tem is less well understood. In this issue of Immunity,
two reports have identified a key pathogenic role for in-
nate immunity via Toll-like receptor and interleukin-23
(IL-23) signaling in the pathogenesis of intestinal inflam-
mation. These data shed light on microbial-immune cell
interactions and the role of cytokines in gut inflamma-
tion (Figure 1). Furthermore, these findings suggest
new avenues for a stratified therapy of inflammatory
bowel diseases.
The inflammatory bowel diseases (IBD: Crohn’s dis-
ease, ulcerative colitis) are chronic relapsing, inflamma-
tory diseases of the gut not due to specific pathogens.
Studies in recent years have highlighted an important
role of the adaptive immune response for the pathogen-
esis of IBD (Neurath et al., 2002). In particular, studies in
genetically engineered systems and in inducible and
adoptive transfer models of chronic intestinal inflamma-
tion have shown a key role of effector T lymphocytes
producing IL-6, IL-13, IL-17, and tumor necrosis factor
(TNF) for the inflammatory process in the gut (Bouma
and Strober, 2003). Importantly, both T helper 1 (Th1)
and Th2 T cells have been shown to cause chronic in-
testinal inflammation. Moreover, a subset of T cells pro-
ducing IL-6 and IL-17, now known as Th17 cells, has
been implicated as an important mediator of experi-
mental colitis in IL-10-deficient mice (Yen et al., 2006).
This subset of T cells is induced by IL-6 and transform-
ing growth factor-b and requires IL-23 for the stabiliza-
tion of its phenotype.
Effector T cells in intestinal inflammation are activated
by microbial antigens. Various studies, including in
germ-free mice, have clearly shown that microbial anti-
gens from the commensal flora can cause a T cell-medi-
ated inflammatory process (Sartor, 2006). The precise
pathways by which microbial antigens activate T lym-
phocytes in gut inflammation have been incompletely
understood but seem to involve surface receptors on
antigen-presenting cells such as dendritic cells (DCs)
and macrophages. The innate immune system relies
on germline-encoded receptors to sense pathogen-de-
rived molecules that are absent in the host (Wagner and
Bauer, 2006). To accomplish this task, the immunesystem possesses Toll-like receptors (TLRs) with differ-
ent specificities for microbial products. Although some
TLRs such as TLR4 and TLR9 may play a protective role
for intestinal epithelial homeostasis in gut injury and
experimental colitis (Fukata et al., 2005), the potential
pathogenic role of TLR signaling in experimental colitis
is poorly understood. Rakoff-Nahoum et al. (2006) have
now demonstrated a key pathogenic role of TLR signal-
ing for chronic intestinal inflammation in IL-10-deficient
mice. Specifically, mice that are deficient in the adaptor
molecule MyD88, which mediates proinflammatory cy-
tokine production in response to TLR ligation, do not
develop colitis on an IL-10-deficient background. In
contrast, mice deficient in both IL-2 and MyD88 exhibit
chronic intestinal inflammation that is comparable to
mice that are deficient only in IL-2, suggesting that TLR
signaling may be essential for some but not all types of
chronic intestinal inflammation. Interestingly, IL-2 and
MyD88 double deficient mice expressed high amounts
of IL-27 but low amounts of the p40 subunit of IL-12
(p35-p40 heterodimer) and IL-23 (p19-p40 heterodimer),
indicating that IL-27 may play a role in mediating the
inflammatory process in the absence of IL-2.
IL-27 is a new bioactive member of the IL-12 cytokine
family composed of an IL-12 p40-related polypeptide,
denoted EBV-induced gene 3 (EBI3), and a unique p28
subunit. Its receptor consists of the orphan receptor
WSX-1 and the widely expressed gp130 protein. The
IL-27 EBI3-p28 heterodimer is known to be induced by
microbial stimuli in antigen-presenting cells such as
DCs via the transcription factor NF-kB. Although IL-27
may suppress innate immune responses via direct ef-
fects on macrophages and granulocytes (Wirtz et al.,
2006), it is a potent inducer of T cell proliferation and
Th1 T cell responses via effects on STAT-1, STAT-3,
and the Th1 master transcription factor T-bet. Although
the data by Rakoff-Nahoum et al. do not prove a pre-
dominant pathogenic role of IL-27 for colitis develop-
ment in IL-2-deficient mice, they clearly suggest that
chronic intestinal inflammation can also be induced in
a TLR-independent fashion via effects of bacterial com-
pounds on antigen-presenting cells, such as lamina
propria dendritic cells (LPDCs), resulting in T cell-medi-
ated intestinal inflammation. Such LPDCs have recently
emerged as a unique class of immune-competent cells
in the gut. In the healthy immune system, they possess
the capacity to sample microbial antigens from the lu-
men by opening up tight junctions between intestinal
epithelial cells and positioning their dendrites into the
lumen (Figure 1). They may also play a key regulatory
role in intestinal inflammation. Experiments with TLR5-
deficient mice (Uematsu et al., 2006) indicate an impor-
tant role of this TLR receptor on LPDCs in mediating up-
take of pathogenic Salmonella. Furthermore, bacterial
flagellin, which is a TLR5 ligand, is a dominant antigen
in patients with complicated courses of Crohn’s disease
(Lodes et al., 2004), suggesting that TLR activation on
LPDCs or other mucosal cells may be important for
the pathogenesis of IBD.
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190Figure 1. Activation of the Mucosal Immune
System in Colitis via Microbial Products
TLR-dependent and TLR-independent path-
ways. Activation of the immune system via
uptake of antigens by antigen-presenting
cells from the gut may lead to colitis. Bacte-
rial DNA sensing by TLR9 or viral single-
stranded RNA (ssRNA) sensing by TLR7
may activate regulatory T cells (Tregs) via
plasmacytoid dendritic cells (DCs), resulting
in protection from experimental colitis. TLR5
signaling via MyD88 may activate lamina
propria dendritic cells (LPDCs) to produce
proinflammatory cytokines (e.g., IL-6, IL-12),
leading to activation of effector T cells and
T cell-dependent inflammation. In addition,
gut T cells may be activated via DCs in
a TLR-independent fashion, resulting in the
production of IL-27 and T cell activation.
Finally, IL-23 may directly induce cytokine
production by cells of the innate immune sys-
tem such as macrophages (M), thereby caus-
ing intestinal inflammation in the absence of
T and B cells.In another report in this issue of Immunity, Uhlig et al.
challenge the dogma that T and B cells are essential for
intestinal inflammation. They found that injection of an
agonistic CD40 antibody into T and B cell-deficient mice
results in histopathologic evidence of colitis, diarrhea,
and weight loss. The development of colitis was associ-
ated with an induction of proinflammatory cytokines
such as IFN-g and TNF in the lamina propria. Moreover,
by using mice deficient in p19 and p35, which are sub-
units of IL-23 and IL-12, Uhlig et al. find that IL-23 but
not IL-12 is required for colonic inflammation, whereas
IL-12 rather than IL-23 controls systemic weight loss
upon administration of agonistic CD40 antibodies.
Taken together, these data indicate an important func-
tion of IL-23 for local initiation of gut inflammation in
the absence of B and T cells. In addition to its effects
on Th17 cells in chronic intestinal inflammation (Yen
et al., 2006), IL-23 thus may directly activate cells of
the mucosal immune system such as macrophages
and LPDCs to produce proinflammatory cytokines and
may emerge as an attractive therapeutic target both
in T cell-dependent (Yen et al., 2006) and T cell-indepen-
dent (Uhlig et al., 2006) colitis. However, IL-23 can inhibit
IL-12 production during initiation of T cell-dependent
colitis induced by the hapten reagent trinitrobenzene
sulfonic acid (TNBS) (our unpublished observations),
and may thereby prevent early Th1 T cell responses in
colitis. Thus, IL-23 seems to be a pleiotropic cytokine
in various models of intestinal inflammation. It appears
that IL-23 has a more prominent role in the mucosal
immune system than in systemic immune responses by
exerting direct effects on both T cells and antigen-pre-
senting cells in the gut. The data by Uhlig et al. suggest
that IL-23 may induce gut inflammation even in theabsence of T cells and thus implicate unique avenues
for T cell-independent therapy of IBD.
The data by Rakoff-Nahoum et al. and Uhlig et al.
substantially extend our current understanding of the
immunopathogenesis of chronic intestinal inflamma-
tion. However, future studies are required to delineate
the role of other TLRs in the intestinal immune system.
In particular, experiments on the role of TLR1, TLR2,
TLR6, and TLR7 are important as well as experiments
on their interactions with other TLRs to identify specific
pathways for gut inflammation. Furthermore, the TLR-
dependent and TLR-independent pathways leading to
production of IL-23 and IL-27 in the mucosal immune
system need to be determined. Nevertheless, the obser-
vations in this issue of Immunity indicate that there are
many roads to chronic gut inflammation, some of which
may involve T cell activation via TLR signaling in anti-
gen-presenting cells, whereas others may be caused
by TLR-independent mechanisms or innate immune
responses in the absence of T and B lymphocytes.
Thus, in spite of a common final Th1 phenotype, colitis
in IL-2-deficient, IL-10-deficient, and CD40-treated mice
develops via different signaling pathways of the innate
immune system involving TLRs, IL-23, or potentially,
IL-27. IBD in humans thus may be regarded as a final
common pathway of gut inflammation in a very heterog-
enous group of diseases caused by diverse mecha-
nisms through which the commensal microflora acti-
vates the mucosal immune system. Although most
forms of IBD are probably driven by the commensal mi-
croflora, there may be substantial differences among
various types of inflammation that are due to the nature
of microbial interaction with the mucosal immune sys-
tem. These data also suggest that the diverse types of
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fied according to immunological parameters and thus
have important implications for the design of individual-
ized therapies in IBD patients in the future. In particular,
one may envision that specific TLR- and IL-23-directed
therapies may be helpful for selective control of innate
and adaptive immune responses in some forms of IBD.
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Avidity and the Art of
Self Non-Self Discrimination
Much has been learned since Jan Klein first defined
immunology as the ‘‘science of self non-self discrimi-
nation.’’ A paper in this issue of Immunity provides
important insight into how such discrimination is
achieved (Zehn and Bevan, 2006).
The generation of lymphocyte repertoires of immense
diversity has allowed vertebrates to survive challenges
from ever-evolving infectious agents. The cost of such
diversity, however, is the risk of generating immune
cells reactive to the individuals own tissues. Vertebrates
have limited this risk by evolving both central and
peripheral tolerance mechanisms. This is especially
important for T lymphocytes, because B lymphocytes
must be able to hypermutate their receptors for affinity
maturation.
Both CD4 and CD8 T cells differentiate in the thymus,
and the process of ‘‘central tolerance’’ weeds out many
potentially autoreactive cells. There seems little doubt,
however, that the thymus does not express all potential
self antigens. Nevertheless, there is clear evidence that
medullary thymic epithelial cells (mTECs) can express
antigens whose expression was previously thought to
be limited to specific organs. Importantly, expression
of many of these proteins is controlled by a single gene
called autoimmune regulatory (Aire) (Su and Anderson,
2004). Aire was first identified by mapping the gene
responsible for autoimmune polyendocrinopathy syn-
drome type 1 (APS-1) in humans. This disease is charac-
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symptoms: Addison’s disease, hypoparathyroidism,
and chronic mucocutaneous candidiasis. APS-1 and
a similar disease found in Aire-deficient mice results
from the failure to delete developing self-targeting
thymocytes.
Many potentially autoreactive T cells escape deletion
in the thymus. There are various mechanisms that allow
CD4 cells to escape deletion (Anderton and Wraith,
2002). For example, T cells specific for the immunodo-
minant epitope of myelin basic protein (MBP) in H-2u
mice escape thymic deletion as a result of low-avidity
antigen recognition. Importantly, the T cell repertoire
of all human beings contains T cells that can readily be
activated with self-antigens, such as MBP, and yet auto-
immune disease associated with such cells is extremely
rare. This then points to the importance of peripheral
tolerance mechanisms.
Lederberg suggested that immature lymphocytes
contacting antigen would be subject to ‘‘clonal abor-
tion,’’ whereas mature cells would be activated. This
concept was supported by later studies showing that
T cells differentiating in the thymus were relatively sen-
sitive to antigen and would be deleted by amounts of
antigen less than the threshold required for activation
of the cells in the periphery (Pircher et al., 1991). Such
a mechanism would be fine for antigens present at simi-
lar or greater amounts in the thymus compared to the
periphery. But what about antigens not expressed in
the thymus or those whose expression in the periphery
could greatly exceed that in the thymus? Here peripheral
tolerance mechanisms would be required to maintain
tolerance. Deletion, anergy, sequestration/ignorance,
and immune regulation all play a part in this process.
Zehn and Bevan describe the Rip-mOva transgenic
mouse that expresses membrane bound ovalbumin in
